MARKET

PVLA

PVLA

Palvella Therapeutics Inc
NASDAQ
13.18
-0.04
-0.30%
Closed 16:00 01/17 EST
OPEN
13.20
PREV CLOSE
13.22
HIGH
13.26
LOW
12.99
VOLUME
15.96K
TURNOVER
--
52 WEEK HIGH
22.32
52 WEEK LOW
6.20
MARKET CAP
147.90M
P/E (TTM)
-1.0452
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PVLA last week (0106-0110)?
Weekly Report · 6d ago
Palvella Therapeutics announces results from Phase 2 study of QTORIN
TipRanks · 01/10 13:16
Palvella Therapeutics Price Target Maintained With a $38.00/Share by HC Wainwright & Co.
Dow Jones · 01/10 13:16
HC Wainwright & Co. Reiterates Buy on Palvella Therapeutics, Maintains $38 Price Target
Benzinga · 01/10 13:06
Palvella Therapeutics Announces Publication Of Phase 2 Trial Results Of QTORIN 3.9% Rapamycin In Journal of Vascular Anomalies
Benzinga · 01/10 13:06
PALVELLA THERAPEUTICS INC - 100% PARTICIPANTS SHOW IMPROVEMENT AFTER 12 WEEKS OF QTORIN RAPAMYCIN
Reuters · 01/10 13:00
Buy Rating Affirmed for Palvella Therapeutics Amid Clinical Progress and Strong Financial Position
TipRanks · 01/10 11:36
Palvella Therapeutics announces first patients dosed in Phase 2 TOIVA trial
TipRanks · 01/08 13:15
More
About PVLA
Palvella Therapeutics, Inc., formerly Pieris Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. The Company is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases. Its lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is in the Phase III SELVA clinical trial in microcystic lymphatic malformations (microcystic LMs) and a Phase II trial in cutaneous venous malformations. It is also engaged in developing treatment for other serious, functionally debilitating skin diseases driven by the overactivation of the mammalian target of rapamycin (mTOR) pathway.

Webull offers Palvella Therapeutics Inc stock information, including NASDAQ: PVLA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PVLA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PVLA stock methods without spending real money on the virtual paper trading platform.